Cell	O
death	O
in	O
amastigote	O
forms	O
of	O
Leishmania	B-OG
amazonensis	I-OG
induced	O
by	O
parthenolide	O

Background	O

Leishmania	B-DS
amazonensis	I-DS
infection	I-DS
results	O
in	O
diverse	O
clinical	O
manifestations	O
:	O
cutaneous	O
,	O
mucocutaneous	O
or	O
visceral	B-DS
leishmaniasis	I-DS
.	O

The	O
arsenal	O
of	O
drugs	O
available	O
for	O
treating	O
Leishmania	B-DS
infections	I-DS
is	O
limited	O
.	O

Therefore	O
,	O
new	O
,	O
effective	O
,	O
and	O
less	O
toxic	O
leishmaniasis	B-DS
treatments	O
are	O
still	O
needed	O
.	O

We	O
verified	O
cell	O
death	O
in	O
amastigote	O
forms	O
of	O
Leishmania	B-OG
amazonensis	I-OG
induced	O
by	O
the	O
sesquiterpene	O
lactone	O
parthenolide	O
.	O

Results	O

The	O
tested	O
compound	O
was	O
able	O
to	O
concentration	O
-	O
dependently	O
affect	O
axenic	O
and	O
intracellular	O
amastigotes	O
,	O
with	O
IC50	O
values	O
of	O
1	O
.	O
3	O
μM	O
and	O
2	O
.	O
9	O
μM	O
,	O
respectively	O
after	O
72	O
h	O
incubation	O
.	O

No	O
genotoxic	O
effects	O
were	O
observed	O
in	O
a	O
micronucleus	O
test	O
in	O
mice	B-OG
.	O

Parthenolide	O
induced	O
morphological	O
and	O
ultrastructural	O
changes	O
in	O
axenic	O
amastigotes	O
,	O
including	O
a	O
loss	O
of	O
membrane	O
integrity	O
,	O
swelling	O
of	O
the	O
mitochondrion	O
,	O
cytoplasmic	O
vacuoles	O
,	O
and	O
intense	O
exocytic	O
activity	O
in	O
the	O
region	O
of	O
the	O
flagellar	O
pocket	O
.	O

These	O
results	O
led	O
us	O
to	O
investigate	O
the	O
occurrence	O
of	O
autophagic	O
vacuoles	O
with	O
monodansylcadaverine	O
and	O
the	O
integrity	O
of	O
the	O
plasma	O
membrane	O
and	O
mitochondrial	O
membrane	O
potential	O
using	O
flow	O
cytometry	O
.	O

In	O
all	O
of	O
the	O
tests	O
,	O
parthenolide	O
had	O
positive	O
results	O
.	O

Conclusions	O

Our	O
results	O
indicate	O
that	O
the	O
antileishmanial	O
action	O
of	O
parthenolide	O
is	O
associated	O
with	O
autophagic	O
vacuole	O
appearance	O
,	O
a	O
reduction	O
of	O
fluidity	O
,	O
a	O
loss	O
of	O
membrane	O
integrity	O
,	O
and	O
mitochondrial	O
dysfunction	O
.	O

Considering	O
the	O
limited	O
repertoire	O
of	O
existing	O
antileishmanial	O
compounds	O
,	O
the	O
products	O
derived	O
from	O
medicinal	O
plants	B-OG
has	O
been	O
one	O
the	O
greatest	O
advances	O
to	O
help	O
develop	O
new	O
chemotherapeutic	O
approaches	O
.	O

Background	O

Leishmaniasis	B-DS
is	O
associated	O
with	O
high	O
morbidity	O
but	O
low	O
mortality	O
.	O

It	O
is	O
a	O
poverty	O
-	O
related	O
disease	O
and	O
has	O
become	O
a	O
serious	O
impediment	O
to	O
socioeconomic	O
development	O
.	O

The	O
true	O
burden	O
of	O
this	O
illness	O
remains	O
unclear	O
because	O
the	O
notification	O
of	O
the	O
disease	O
is	O
compulsory	O
in	O
only	O
32	O
of	O
the	O
88	O
affected	O
countries	O
,	O
and	O
most	O
of	O
the	O
affected	O
people	O
live	O
in	O
remote	O
areas	O
.	O

Additionally	O
,	O
the	O
disfiguring	O
scars	O
caused	O
by	O
Leishmania	B-OG
keep	O
patients	O
hidden	O
.	O

An	O
estimated	O
1	O
.	O
5	O
million	O
new	O
cases	O
of	O
cutaneous	B-DS
leishmaniasis	I-DS
and	O
500	O
,	O
000	O
cases	O
of	O
visceral	B-DS
leishmaniasis	I-DS
occur	O
annually	O
,	O
with	O
approximately	O
12	O
million	O
people	O
currently	O
infected	O
[	O
1	O
].	O

Moreover	O
,	O
cases	O
of	O
Leishmania	B-OG
and	O
human	B-DS
immunodeficiency	I-DS
virus	I-DS
co	I-DS
-	I-DS
infection	I-DS
are	O
becoming	O
more	O
frequent	O
[	O
2	O
,	O
3	O
].	O

Leishmania	B-DS
(	I-DS
Leishmania	I-DS
)	I-DS
amazonensis	I-DS
infection	I-DS
results	O
in	O
diverse	O
clinical	O
manifestations	O
,	O
ranging	O
from	O
cutaneous	O
to	O
mucocutaneous	O
or	O
visceral	O
involvement	O
[	O
4	O
].	O

This	O
is	O
attributable	O
to	O
the	O
genetic	O
diversity	O
of	O
L	B-OG
.	I-OG
amazonensis	I-OG
strains	O
,	O
and	O
this	O
divergence	O
extends	O
to	O
variations	O
of	O
chromosome	O
size	O
[	O
5	O
].	O

The	O
arsenal	O
of	O
drugs	O
available	O
for	O
treating	O
Leishmania	B-DS
infections	I-DS
is	O
limited	O
.	O

The	O
basic	O
treatment	O
consists	O
of	O
administering	O
pentavalent	O
antimonial	O
compounds	O
[	O
6	O
].	O

However	O
,	O
the	O
choice	O
of	O
medication	O
depends	O
on	O
the	O
species	O
involved	O
and	O
type	O
of	O
clinical	O
manifestation	O
[	O
7	O
].	O

The	O
usefulness	O
of	O
antileishmanial	O
drugs	O
has	O
been	O
limited	O
by	O
their	O
toxicity	O
,	O
and	O
treatment	O
failure	O
is	O
often	O
attributable	O
to	O
drug	O
resistance	O
[	O
8	O
].	O

To	O
solve	O
this	O
problem	O
,	O
developing	O
less	O
toxic	O
drugs	O
and	O
discovering	O
cellular	O
and	O
molecular	O
markers	O
in	O
parasites	O
to	O
identify	O
the	O
phenotype	O
of	O
chemoresistance	O
against	O
leishmanicidal	O
drugs	O
are	O
necessary	O
[	O
8	O
,	O
9	O
].	O

These	O
problems	O
led	O
to	O
the	O
development	O
of	O
additional	O
antileishmanial	O
drugs	O
.	O

Some	O
drug	O
-	O
delivery	O
systems	O
,	O
plants	B-OG
,	O
and	O
synthetic	O
compounds	O
are	O
being	O
developed	O
as	O
effective	O
treatments	O
for	O
the	O
disease	O
[	O
7	O
].	O

Previous	O
studies	O
demonstrated	O
the	O
in	O
vitro	O
activity	O
of	O
parthenolide	O
,	O
a	O
sesquiterpene	O
lactone	O
purified	O
from	O
Tanacetum	B-OG
parthenium	I-OG
,	O
against	O
promastigotes	O
and	O
intracellular	O
amastigotes	O
(	O
inside	O
J774G8	O
macrophages	O
)	O
of	O
L	B-OG
.	I-OG
amazonensis	I-OG
[	O
10	O
].	O

Moreover	O
,	O
significant	O
alterations	O
in	O
promastigote	O
forms	O
were	O
demonstrated	O
by	O
light	O
microscopy	O
and	O
scanning	O
and	O
transmission	O
electron	O
microscopy	O
[	O
11	O
].	O

We	O
evaluated	O
the	O
activity	O
of	O
parthenolide	O
against	O
L	B-OG
.	I-OG
amazonensis	I-OG
axenic	O
amastigotes	O
and	O
demonstrated	O
a	O
possible	O
mechanism	O
of	O
action	O
of	O
this	O
compound	O
in	O
this	O
life	O
stage	O
of	O
the	O
parasite	O
.	O

Results	O

Antileishmanial	O
assays	O

The	O
addition	O
of	O
4	O
.	O
0	O
μM	O
parthenolide	O
to	O
the	O
culture	O
of	O
axenic	O
amastigotes	O
induced	O
growth	O
arrest	O
and	O
partial	O
cell	O
lysis	O
after	O
48	O
h	O
(	O
i	O
.	O
e	O
.,	O
growth	O
inhibition	O
up	O
to	O
90	O
%).	O

When	O
the	O
cells	O
were	O
treated	O
with	O
2	O
.	O
0	O
μM	O
parthenolide	O
,	O
the	O
percentage	O
of	O
growth	O
inhibition	O
was	O
approximately	O
70	O
%.	O

Parthenolide	O
had	O
an	O
IC50	O
of	O
1	O
.	O
3	O
μM	O
and	O
IC90	O
of	O
3	O
.	O
3	O
μM	O
after	O
72	O
h	O
incubation	O
(	O
Figure	O
1A	O
).	O

Effects	O
of	O
parthenolide	O
(	O
A	O
)	O
and	O
amphotericin	O
B	O
(	O
B	O
)	O
on	O
the	O
growth	O
of	O
L	B-OG
.	I-OG
amazonensis	I-OG
axenic	O
amastigotes	O
.	O
After	O
treatment	O
with	O
different	O
concentrations	O
of	O
the	O
drugs	O
,	O
parasites	O
were	O
counted	O
,	O
and	O
the	O
percentage	O
of	O
parasite	O
growth	O
inhibition	O
was	O
determined	O
daily	O
for	O
120	O
h	O
.	O

The	O
data	O
indicate	O
the	O
average	O
of	O
the	O
two	O
independent	O
experiments	O
performed	O
twice	O
.	O

Statistical	O
analysis	O
:	O
the	O
data	O
of	O
each	O
incubation	O
period	O
were	O
compared	O
statistically	O
at	O
p	O
<	O
0	O
.	O
05	O
.	O

Bars	O
that	O
are	O
not	O
indicated	O
with	O
letters	O
in	O
common	O
are	O
statistically	O
different	O
.	O

A	O
concentration	O
of	O
1	O
.	O
0	O
or	O
0	O
.	O
5	O
μM	O
of	O
the	O
reference	O
drug	O
amphotericin	O
B	O
inhibited	O
more	O
than	O
93	O
%	O
of	O
L	B-OG
.	I-OG
amazonensis	I-OG
amastigote	O
cell	O
growth	O
.	O

This	O
drug	O
had	O
an	O
IC50	O
and	O
IC90	O
of	O
0	O
.	O
22	O
μM	O
and	O
0	O
.	O
45	O
μM	O
,	O
respectively	O
,	O
after	O
culturing	O
for	O
72	O
h	O
(	O
Figure	O
1B	O
).	O

Parthenolide	O
also	O
inhibited	O
the	O
growth	O
of	O
intracellular	O
amastigotes	O
in	O
mouse	B-OG
resident	O
peritoneal	O
macrophages	O
after	O
24	O
h	O
incubation	O
.	O

Treatment	O
with	O
4	O
.	O
0	O
,	O
3	O
.	O
2	O
,	O
2	O
.	O
4	O
,	O
and	O
1	O
.	O
6	O
μM	O
parthenolide	O
reduced	O
the	O
proliferation	O
of	O
parasites	O
into	O
macrophages	O
(	O
survival	O
index	O
)	O
by	O
82	O
.	O
5	O
,	O
59	O
.	O
4	O
,	O
37	O
.	O
3	O
,	O
and	O
6	O
.	O
1	O
%,	O
respectively	O
,	O
compared	O
with	O
the	O
control	O
.	O

The	O
survival	O
index	O
indicated	O
that	O
parthenolide	O
inhibited	O
the	O
intracellular	O
viability	O
and	O
multiplication	O
of	O
Leishmania	B-OG
in	O
infected	O
murine	O
macrophages	O
and	O
showed	O
50	O
%	O
inhibition	O
of	O
cell	O
survival	O
at	O
a	O
concentration	O
of	O
2	O
.	O
9	O
μM	O
(	O
Figure	O
2	O
).	O

Effect	O
of	O
parthenolide	O
on	O
amastigotes	O
of	O
L	B-OG
.	I-OG
amazonensis	I-OG
in	O
mouse	B-OG
resident	O
peritoneal	O
macrophages	O
.	O
Peritoneal	O
macrophage	O
cells	O
were	O
infected	O
with	O
promastigote	O
forms	O
,	O
and	O
then	O
intracellular	O
amastigotes	O
were	O
treated	O
with	O
different	O
concentrations	O
of	O
parthenolide	O
.	O

After	O
24	O
h	O
treatment	O
,	O
the	O
survival	O
index	O
was	O
calculated	O
by	O
multiplying	O
the	O
percentage	O
of	O
macrophages	O
with	O
internalized	O
parasites	O
and	O
mean	O
number	O
of	O
internalized	O
parasites	O
per	O
macrophage	O
.	O

The	O
results	O
shown	O
are	O
from	O
one	O
representative	O
experiment	O
of	O
two	O
independent	O
experiments	O
performed	O
in	O
duplicate	O
.	O

The	O
data	O
were	O
compared	O
statistically	O
at	O
p	O
<	O
0	O
.	O
05	O
.	O

Bars	O
that	O
are	O
not	O
indicated	O
with	O
letters	O
in	O
common	O
are	O
statistically	O
different	O
.	O

Previous	O
studies	O
showed	O
that	O
when	O
J774G8	O
murine	O
macrophages	O
were	O
treated	O
with	O
parthenolide	O
,	O
the	O
50	O
%	O
cytotoxic	O
concentration	O
(	O
CC50	O
)	O
was	O
56	O
.	O
4	O
μM	O
[	O
10	O
].	O

By	O
comparing	O
the	O
toxicity	O
for	O
J774G8	O
macrophages	O
and	O
activity	O
against	O
intracellular	O
amastigotes	O
,	O
obtaining	O
the	O
selectivity	O
index	O
ratio	O
is	O
possible	O
(	O
CC50	O
for	O
J774G8	O
cells	O
/	O
IC50	O
for	O
protozoa	B-OG
).	O

In	O
the	O
present	O
study	O
,	O
parthenolide	O
had	O
an	O
IC50	O
of	O
2	O
.	O
9	O
μM	O
,	O
presenting	O
a	O
selectivity	O
index	O
ratio	O
of	O
19	O
.	O
4	O
(	O
i	O
.	O
e	O
.,	O
the	O
compound	O
is	O
19	O
.	O
4	O
-	O
times	O
more	O
selective	O
against	O
parasites	O
than	O
host	O
cells	O
).	O

Mutagenicity	O
evaluation	O

The	O
results	O
of	O
the	O
in	O
vivo	O
bone	O
marrow	O
micronucleus	O
test	O
in	O
rats	B-OG
are	O
shown	O
in	O
Table	O
1	O
.	O

Parthenolide	O
did	O
not	O
induce	O
genotoxic	O
effects	O
at	O
a	O
concentration	O
of	O
3	O
.	O
75	O
mg	O
/	O
kg	O
body	O
weight	O
,	O
with	O
no	O
significant	O
increase	O
in	O
the	O
frequency	O
of	O
MNPCE	O
(	O
10	O
.	O
0	O
±	O
1	O
.	O
6	O
)	O
compared	O
with	O
the	O
vehicle	O
control	O
group	O
(	O
7	O
.	O
0	O
±	O
1	O
.	O
8	O
).	O

In	O
contrast	O
,	O
a	O
significant	O
increase	O
in	O
the	O
frequency	O
of	O
MNPCE	O
was	O
observed	O
in	O
the	O
positive	O
control	O
group	O
(	O
cyclophosphamide	O
;	O
27	O
.	O
0	O
±	O
4	O
.	O
0	O
).	O

In	O
the	O
present	O
study	O
,	O
no	O
clinical	O
signs	O
of	O
toxicity	O
were	O
observed	O
in	O
treated	O
animals	B-OG
.	O

However	O
,	O
further	O
studies	O
should	O
be	O
performed	O
with	O
higher	O
concentrations	O
of	O
parthenolide	O
to	O
exclude	O
the	O
possibility	O
of	O
genotoxicity	O
.	O

Micronucleated	O
polychromatic	O
erythrocyte	O
(	O
MNPCE	O
)	O
score	O
in	O
2	O
,	O
000	O
reticulocytes	O
from	O
bone	O
marrow	O
of	O
mice	B-OG

Treatment	O

MNPCE	O
(	O
mean	O
±	O
SD	O
)	O

Vehicle	O

7	O
.	O
0	O
±	O
1	O
.	O
8	O

Cyclophosphamide	O

27	O
.	O
0	O
±	O
4	O
.	O
0b	O

Parthenolide	O

10	O
.	O
0	O
±	O
1	O
.	O
6a	O

Findings	O
after	O
24	O
h	O
oral	O
treatment	O
with	O
vehicle	O
(	O
negative	O
control	O
),	O
cyclophosphamide	O
(	O
positive	O
control	O
),	O
and	O
parthenolide	O
.	O

aNo	O
significant	O
difference	O
compared	O
with	O
negative	O
control	O
and	O
significant	O
difference	O
compared	O
with	O
positive	O
control	O
(	O
p	O
<	O
0	O
.	O
05	O
).	O

bSignificant	O
difference	O
compared	O
with	O
negative	O
control	O
(	O
p	O
<	O
0	O
.	O
05	O
).	O

Scanning	O
and	O
transmission	O
electron	O
microscopy	O

To	O
determine	O
the	O
morphological	O
and	O
ultrastructural	O
changes	O
in	O
L	B-OG
.	I-OG
amazonensis	I-OG
axenic	O
amastigotes	O
induced	O
by	O
parthenolide	O
,	O
the	O
cells	O
were	O
treated	O
with	O
the	O
IC50	O
(	O
1	O
.	O
3	O
μM	O
)	O
of	O
the	O
compound	O
.	O

Untreated	O
controls	O
showed	O
no	O
morphological	O
(	O
Figure	O
3A	O
)	O
or	O
ultrastructural	O
(	O
Figure	O
3D	O
)	O
differences	O
.	O

Similarly	O
,	O
cells	O
incubated	O
with	O
0	O
.	O
05	O
%	O
DMSO	O
(	O
i	O
.	O
e	O
.,	O
the	O
same	O
concentration	O
used	O
in	O
the	O
final	O
solutions	O
of	O
parthenolide	O
)	O
remained	O
unaltered	O
(	O
data	O
not	O
shown	O
).	O

When	O
treated	O
with	O
parthenolide	O
,	O
changes	O
in	O
form	O
were	O
visualized	O
by	O
scanning	O
electron	O
microscopy	O
(	O
Figure	O
3B	O
and	O
C	O
).	O

Transmission	O
electron	O
microscopy	O
showed	O
a	O
loss	O
of	O
membrane	O
integrity	O
associated	O
with	O
amphotericin	O
B	O
exposure	O
at	O
the	O
IC50	O
concentration	O
(	O
Figure	O
3E	O
).	O

Parthenolide	O
caused	O
intense	O
swelling	O
of	O
the	O
mitochondrion	O
(	O
Figure	O
3F	O
)	O
and	O
cytoplasmic	O
blebbing	O
(	O
Figure	O
3G	O
).	O

Finally	O
,	O
the	O
ultrastructural	O
analysis	O
showed	O
that	O
amastigotes	O
treated	O
with	O
parthenolide	O
formed	O
multiple	O
cytoplasmic	O
vacuoles	O
(	O
Figure	O
3H	O
),	O
and	O
intense	O
exocytic	O
activity	O
was	O
observed	O
in	O
the	O
region	O
of	O
the	O
flagellar	O
pocket	O
,	O
appearing	O
as	O
concentric	O
membranes	O
within	O
the	O
pocket	O
(	O
Figure	O
3I	O
).	O

Scanning	O
(	O
A	O
-	O
C	O
)	O
and	O
transmission	O
(	O
D	O
-	O
I	O
)	O
electron	O
microscopy	O
of	O
axenic	O
amastigotes	O
of	O
L	B-OG
.	I-OG
amazonensis	I-OG
treated	O
with	O
parthenolide	O
.	O
Amastigotes	O
were	O
incubated	O
for	O
72	O
h	O
in	O
the	O
absence	O
(	O
A	O
and	O
D	O
)	O
or	O
presence	O
(	O
B	O
,	O
C	O
,	O
F	O
-	O
I	O
)	O
of	O
the	O
IC50	O
(	O
1	O
.	O
3	O
μM	O
)	O
of	O
parthenolide	O
.	O

For	O
transmission	O
electron	O
microscopy	O
,	O
the	O
treatment	O
of	O
amastigotes	O
was	O
also	O
accomplished	O
using	O
the	O
IC50	O
of	O
amphotericin	O
B	O
as	O
a	O
reference	O
drug	O
that	O
acts	O
on	O
the	O
cytoplasmic	O
membrane	O
(	O
E	O
).	O

The	O
arrows	O
indicate	O
plasma	O
membrane	O
blebs	O
or	O
loss	O
of	O
membrane	O
integrity	O
,	O
and	O
the	O
asterisks	O
indicate	O
vesicles	O
located	O
in	O
the	O
cytoplasm	O
or	O
flagellar	O
pocket	O
.	O
n	O
,	O
nucleus	O
;	O
f	O
,	O
flagellum	O
;	O
fp	O
,	O
flagellar	O
pocket	O
;	O
m	O
,	O
mitochondrion	O
;	O
k	O
,	O
kinetoplast	O
.	O

Scale	O
bars	O
=	O
1	O
μm	O
.	O

Labeling	O
of	O
autophagic	O
vacuoles	O
with	O
monodansylcadaverine	O

We	O
studied	O
the	O
incorporation	O
of	O
monodancylcadaverine	O
(	O
MDC	O
)	O
in	O
cells	O
in	O
which	O
autophagy	O
was	O
stimulated	O
by	O
parthenolide	O
.	O

Axenic	O
amastigotes	O
treated	O
with	O
the	O
IC50	O
(	O
Figure	O
4B	O
)	O
or	O
IC90	O
(	O
Figure	O
4C	O
)	O
of	O
parthenolide	O
showed	O
an	O
increase	O
in	O
the	O
number	O
of	O
vesicles	O
,	O
indicating	O
that	O
the	O
compound	O
induced	O
the	O
formation	O
of	O
MDC	O
-	O
labeled	O
vacuoles	O
in	O
the	O
cytoplasm	O
.	O

MDC	O
-	O
positive	O
cells	O
were	O
visualized	O
in	O
treated	O
cells	O
but	O
not	O
in	O
control	O
cells	O
(	O
Figure	O
4A	O
)	O
or	O
amphotericin	O
-	O
treated	O
cells	O
(	O
data	O
not	O
shown	O
).	O

These	O
results	O
show	O
that	O
parthenolide	O
treatment	O
,	O
unlike	O
amphotericin	O
B	O
,	O
led	O
to	O
the	O
formation	O
of	O
autophagic	O
vacuoles	O
in	O
L	B-OG
.	I-OG
amazonensis	I-OG
amastigotes	O
.	O

Monodansylcadaverine	O
(	O
MDC	O
)-	O
labeled	O
vesicles	O
in	O
axenic	O
amastigotes	O
of	O
L	B-OG
.	I-OG
amazonensis	I-OG
induced	O
by	O
parthenolide	O
treatment	O
.	O
Amastigotes	O
were	O
incubated	O
for	O
72	O
h	O
in	O
Schneider	O
medium	O
(	O
control	O
cells	O
)	O
(	O
A	O
)	O
or	O
in	O
the	O
presence	O
of	O
the	O
IC50	O
(	O
B	O
)	O
or	O
IC90	O
(	O
C	O
)	O
of	O
parthenolide	O
.	O

The	O
data	O
are	O
representative	O
of	O
at	O
least	O
three	O
independent	O
experiments	O
.	O

Scale	O
bars	O
=	O
5	O
μm	O
.	O

Flow	O
cytometric	O
measurement	O
of	O
amastigote	O
culture	O

Live	O
L	B-OG
.	I-OG
amazonensis	I-OG
cells	O
were	O
incubated	O
with	O
propidium	O
iodide	O
and	O
rhodamine	O
123	O
,	O
and	O
fluorescence	O
was	O
measured	O
by	O
flow	O
cytometry	O
.	O

The	O
gated	O
percentage	O
of	O
propidium	O
iodide	O
-	O
stained	O
amastigotes	O
after	O
treatment	O
with	O
amphotericin	O
B	O
(	O
positive	O
control	O
)	O
was	O
71	O
.	O
4	O
%,	O
much	O
higher	O
than	O
untreated	O
parasites	O
(	O
negative	O
control	O
)	O
that	O
presented	O
6	O
.	O
0	O
%	O
(	O
Figure	O
5A	O
).	O

When	O
the	O
cells	O
were	O
treated	O
with	O
20	O
and	O
40	O
μM	O
parthenolide	O
,	O
the	O
percentages	O
of	O
labeled	O
amastigotes	O
were	O
34	O
.	O
2	O
%	O
and	O
56	O
.	O
2	O
%,	O
respectively	O
(	O
Figure	O
5B	O
),	O
possibly	O
indicating	O
a	O
considerable	O
increase	O
in	O
plasma	O
membrane	O
permeability	O
.	O

To	O
prove	O
that	O
Leishmania	B-OG
cells	O
functionally	O
respond	O
to	O
the	O
pharmacological	O
alteration	O
of	O
ΔΨm	O
,	O
amastigotes	O
were	O
treated	O
with	O
the	O
protonophore	O
carbonyl	O
cyanide	O
m	O
-	O
chlorophenylhydrazone	O
(	O
CCCP	O
),	O
which	O
has	O
been	O
shown	O
to	O
interfere	O
with	O
mitochondrial	O
membrane	O
potential	O
in	O
various	O
cell	O
types	O
[	O
12	O
].	O

The	O
results	O
showed	O
that	O
82	O
.	O
5	O
%	O
of	O
the	O
amastigotes	O
without	O
treatment	O
(	O
negative	O
control	O
)	O
presented	O
a	O
maximal	O
increase	O
in	O
fluorescence	O
,	O
and	O
with	O
200	O
μM	O
CCCP	O
,	O
46	O
.	O
7	O
%	O
showed	O
fluorescence	O
,	O
indicating	O
a	O
loss	O
of	O
ΔΨm	O
(	O
Figure	O
5C	O
).	O

We	O
next	O
observed	O
ΔΨm	O
reductions	O
of	O
68	O
.	O
4	O
%	O
and	O
56	O
.	O
1	O
%	O
when	O
the	O
amastigotes	O
were	O
treated	O
with	O
20	O
and	O
40	O
μM	O
parthenolide	O
,	O
respectively	O
,	O
suggesting	O
that	O
this	O
compound	O
interferes	O
with	O
the	O
mitochondrial	O
membrane	O
potential	O
leading	O
to	O
alteration	O
of	O
ATP	O
generation	O
and	O
in	O
consequence	O
cell	O
damage	O
takes	O
place	O
.	O

Flow	O
cytometry	O
analysis	O
of	O
propidium	O
iodide	O
-	O
(	O
A	O
,	O
B	O
)	O
and	O
rhodamine	O
123	O
-	O
(	O
C	O
,	O
D	O
)	O
labeled	O
axenic	O
amastigotes	O
of	O
L	B-OG
.	I-OG
amazonensis	I-OG
.	O

(	O
A	O
)	O
Untreated	O
cells	O
:	O
negative	O
control	O
(	O
C	O
-)	O
and	O
amphotericin	O
B	O
as	O
positive	O
control	O
(	O
C	O
+).	O
(	O
B	O
)	O
Amastigotes	O
treated	O
with	O
20	O
or	O
40	O
μM	O
parthenolide	O
(	O
Pt	O
20	O
or	O
Pt	O
40	O
).	O
(	O
C	O
)	O
Untreated	O
cells	O
:	O
negative	O
control	O
and	O
carbonyl	O
cyanide	O
m	O
-	O
chlorophenylhydrazone	O
as	O
a	O
positive	O
control	O
.	O
(	O
D	O
)	O
Amastigotes	O
treated	O
with	O
20	O
or	O
40	O
μM	O
parthenolide	O
(	O
Pt	O
20	O
or	O
Pt	O
40	O
).	O

The	O
data	O
are	O
representative	O
of	O
at	O
least	O
two	O
independent	O
experiments	O
.	O

EPR	O
spectra	O
of	O
spin	O
-	O
labeled	O
Leishmania	B-OG

The	O
experimental	O
and	O
best	O
-	O
fit	O
EPR	O
spectra	O
of	O
spin	O
-	O
label	O
5	O
-	O
DSA	O
structured	O
in	O
the	O
plasma	O
membrane	O
of	O
Leishmania	B-OG
are	O
shown	O
in	O
Figure	O
6	O
.	O

These	O
EPR	O
spectra	O
are	O
typical	O
for	O
cellular	O
membranes	O
that	O
contain	O
an	O
appreciable	O
amount	O
of	O
integral	O
proteins	O
.	O

Treatment	O
with	O
parthenolide	O
increased	O
two	O
EPR	O
parameters	O
,	O
the	O
outer	O
hyperfine	O
splitting	O
,	O
2A	O
//,	O
and	O
rotational	O
correlation	O
time	O
,	O
τC	O
,	O
indicating	O
a	O
significant	O
reduction	O
of	O
membrane	O
lipid	O
dynamics	O
.	O

2A	O
//	O
is	O
a	O
practice	O
parameter	O
measured	O
directly	O
in	O
EPR	O
spectra	O
that	O
has	O
been	O
widely	O
used	O
to	O
monitor	O
membrane	O
fluidity	O
,	O
although	O
in	O
principle	O
it	O
is	O
a	O
static	O
parameter	O
associated	O
with	O
the	O
orientation	O
distribution	O
of	O
the	O
spin	O
labels	O
in	O
the	O
membrane	O
.	O

The	O
theoretical	O
EPR	O
spectrum	O
of	O
spin	O
-	O
label	O
5	O
-	O
DSA	O
in	O
the	O
plasma	O
membrane	O
of	O
Leishmania	B-OG
was	O
best	O
fitted	O
using	O
a	O
model	O
of	O
two	O
spectral	O
components	O
.	O

This	O
indicates	O
that	O
the	O
membrane	O
has	O
two	O
populations	O
of	O
spin	O
labels	O
of	O
distinct	O
mobility	O
.	O

The	O
EPR	O
spectra	O
of	O
spin	O
labels	O
in	O
lipid	O
bilayers	O
are	O
well	O
known	O
to	O
contain	O
proteins	O
sometimes	O
composed	O
of	O
two	O
spectral	O
components	O
.	O

The	O
more	O
restricted	O
component	O
is	O
associated	O
with	O
boundary	O
lipids	O
where	O
the	O
spin	O
labels	O
surround	O
the	O
hydrophobic	O
regions	O
of	O
proteins	O
,	O
whereas	O
the	O
more	O
mobile	O
component	O
arises	O
from	O
the	O
spin	O
labels	O
located	O
in	O
the	O
bulk	O
bilayer	O
phase	O
,	O
away	O
from	O
the	O
protein	O
[	O
13	O
].	O

The	O
fitting	O
program	O
provides	O
the	O
τ	O
c	O
and	O
population	O
of	O
each	O
component	O
.	O

Thus	O
,	O
the	O
mean	O
of	O
the	O
rotational	O
correlation	O
time	O
was	O
calculated	O
as	O
τ	O
c	O
=	O
N	O
1	O
*	O
τ	O
c1	O
+	O
N	O
2	O
*	O
τ	O
c2	O
,	O
in	O
which	O
N	O
1	O
and	O
N	O
2	O
are	O
the	O
fractions	O
of	O
the	O
population	O
in	O
components	O
1	O
and	O
2	O
,	O
respectively	O
,	O
and	O
τ	O
c1	O
and	O
τ	O
c2	O
are	O
the	O
corresponding	O
rotational	O
time	O
correlations	O
.	O

Experimental	O
EPR	O
spectra	O
(	O
black	O
line	O
)	O
and	O
theoretical	O
fits	O
(	O
red	O
line	O
)	O
of	O
spin	O
-	O
label	O
5	O
-	O
DSA	O
in	O
Leishmania	B-OG
membrane	O
.	O
The	O
experiment	O
was	O
conducted	O
at	O
26	O
°	O
C	O
for	O
samples	O
untreated	O
and	O
treated	O
with	O
parthenolide	O
at	O
the	O
indicated	O
concentrations	O
.	O

EPR	O
spectra	O
were	O
simulated	O
with	O
the	O
NLLS	O
fitting	O
program	O
,	O
and	O
the	O
values	O
of	O
the	O
parameter	O
rotational	O
correlation	O
time	O
,	O
τC	O
,	O
obtained	O
from	O
the	O
fit	O
for	O
each	O
spectrum	O
are	O
indicated	O
on	O
a	O
nanosecond	O
scale	O
.	O

The	O
EPR	O
parameter	O
2A	O
//	O
is	O
the	O
separation	O
in	O
magnetic	O
-	O
field	O
units	O
between	O
the	O
first	O
and	O
last	O
resonance	O
lines	O
of	O
the	O
spectrum	O
.	O

The	O
vertical	O
lines	O
indicate	O
the	O
2A	O
//	O
for	O
the	O
control	O
samples	O
,	O
and	O
the	O
smaller	O
vertical	O
lines	O
illustrate	O
the	O
increase	O
in	O
2A	O
//	O
for	O
the	O
sample	O
treated	O
with	O
9	O
×	O
109	O
molecules	O
/	O
cell	O
.	O

The	O
measured	O
2A	O
//	O
values	O
and	O
τC	O
values	O
indicate	O
that	O
the	O
presence	O
of	O
parthenolide	O
significantly	O
reduced	O
lipid	O
fluidity	O
.	O

The	O
estimated	O
experimental	O
errors	O
for	O
the	O
2A	O
//	O
and	O
τC	O
parameters	O
are	O
0	O
.	O
5	O
G	O
and	O
1	O
.	O
0	O
ns	O
,	O
respectively	O
.	O

Discussion	O

For	O
many	O
years	O
,	O
parasites	O
of	O
the	O
genus	O
Leishmania	B-OG
have	O
displayed	O
extraordinary	O
plasticity	O
to	O
face	O
modifications	O
in	O
their	O
environment	O
[	O
14	O
].	O

The	O
expansion	O
of	O
risk	O
factors	O
related	O
to	O
environmental	O
changes	O
and	O
man	B-OG
-	O
made	O
transformations	O
are	O
making	O
leishmaniasis	B-DS
a	O
growing	O
public	O
health	O
concern	O
in	O
many	O
countries	O
worldwide	O
[	O
15	O
].	O

Leishmaniasis	B-DS
urgently	O
needs	O
novel	O
drugs	O
with	O
improved	O
features	O
,	O
and	O
many	O
compounds	O
primarily	O
derived	O
from	O
plants	B-OG
are	O
promising	O
leads	O
for	O
the	O
development	O
of	O
novel	O
chemotherapeutics	O
[	O
16	O
].	O

The	O
development	O
of	O
axenic	O
cultures	O
of	O
amastigotes	O
of	O
Leishmania	B-OG
species	O
yielded	O
new	O
opportunities	O
to	O
investigate	O
the	O
antileishmanial	O
activities	O
of	O
new	O
compounds	O
directly	O
at	O
the	O
mammalian	O
stage	O
of	O
the	O
parasite	O
[	O
17	O
].	O

Assays	O
that	O
use	O
intracellular	O
amastigote	O
cell	O
cultures	O
are	O
relevant	O
because	O
this	O
life	O
cycle	O
stage	O
of	O
the	O
parasite	O
is	O
important	O
to	O
its	O
pathogenicity	O
,	O
and	O
data	O
obtained	O
exclusively	O
from	O
promastigote	O
cell	O
lines	O
are	O
insufficient	O
[	O
16	O
].	O

Therefore	O
,	O
in	O
the	O
present	O
study	O
,	O
we	O
determined	O
the	O
leishmanicidal	O
activity	O
of	O
parthenolide	O
,	O
which	O
is	O
naturally	O
occurring	O
,	O
in	O
both	O
axenic	O
and	O
intracellular	O
amastigotes	O
.	O

To	O
discover	O
better	O
leishmanicidal	O
compounds	O
,	O
the	O
isolation	O
and	O
purification	O
of	O
the	O
active	O
ingredients	O
of	O
medicinal	O
plants	B-OG
are	O
gaining	O
attention	O
[	O
18	O
].	O

Many	O
new	O
natural	O
product	O
groups	O
,	O
such	O
as	O
terpenes	O
,	O
have	O
exhibited	O
antiprotozoal	O
potential	O
and	O
attracted	O
renewed	O
interest	O
with	O
surprising	O
efficacy	O
and	O
selectivity	O
[	O
19	O
].	O

Parthenolide	O
is	O
a	O
lipophilic	O
hydrocarbon	O
compound	O
formed	O
by	O
units	O
of	O
isoprene	O
.	O

The	O
accumulation	O
of	O
lipophilic	O
compounds	O
in	O
the	O
cytoplasmic	O
membrane	O
and	O
membrane	O
constituents	O
of	O
microorganisms	O
has	O
considerable	O
effects	O
on	O
the	O
loss	O
of	O
cellular	O
integrity	O
and	O
inhibition	O
of	O
respiratory	O
cellular	O
activity	O
in	O
mitochondria	O
[	O
20	O
].	O

This	O
interaction	O
with	O
cell	O
membranes	O
eventually	O
leads	O
to	O
cell	O
death	O
.	O

In	O
our	O
research	O
,	O
parthenolide	O
had	O
antileishmanial	O
effects	O
against	O
axenic	O
and	O
intracellular	O
amastigotes	O
of	O
L	B-OG
.	I-OG
amazonensis	I-OG
presenting	O
IC50	O
of	O
1	O
.	O
3	O
after	O
72	O
h	O
growth	O
and	O
2	O
.	O
9	O
μM	O
after	O
24	O
h	O
growth	O
,	O
respectively	O
.	O

The	O
differences	O
in	O
IC50	O
values	O
can	O
be	O
explained	O
because	O
the	O
experiments	O
with	O
axenic	O
amastigotes	O
are	O
directed	O
against	O
the	O
relevant	O
stage	O
of	O
the	O
parasite	O
whereas	O
the	O
use	O
of	O
intracellular	O
amastigotes	O
will	O
give	O
essential	O
information	O
on	O
the	O
capacity	O
of	O
the	O
drugs	O
to	O
target	O
intracellular	O
organisms	O
.	O

The	O
role	O
played	O
by	O
the	O
macrophages	O
on	O
drug	O
-	O
mediated	O
toxicity	O
may	O
be	O
important	O
.	O

Their	O
presence	O
may	O
limit	O
the	O
availability	O
of	O
the	O
compounds	O
under	O
evaluation	O
[	O
21	O
,	O
22	O
].	O

The	O
toxicity	O
for	O
J774G8	O
macrophages	O
and	O
the	O
activity	O
against	O
intracellular	O
amastigotes	O
were	O
compared	O
by	O
using	O
the	O
selectivity	O
index	O
ratio	O
(	O
CC50	O
for	O
J774G8	O
cells	O
/	O
IC50	O
for	O
protozoa	B-OG
)	O
[	O
10	O
].	O

The	O
parthenolide	O
was	O
more	O
selective	O
against	O
the	O
intracellular	O
amastigotes	O
than	O
the	O
mammalian	O
cells	O
,	O
with	O
a	O
selectivity	O
index	O
ratio	O
of	O
19	O
.	O
4	O
.	O

It	O
is	O
generally	O
considered	O
that	O
biological	O
efficacy	O
is	O
not	O
due	O
to	O
in	O
vitro	O
cytotoxicity	O
when	O
this	O
index	O
is	O
≥	O
10	O
[	O
23	O
,	O
24	O
].	O

The	O
low	O
toxicity	O
against	O
mammalian	O
cells	O
is	O
an	O
important	O
criterion	O
in	O
the	O
search	O
for	O
active	O
compounds	O
with	O
antiprotozoal	O
activity	O
.	O

For	O
this	O
purpose	O
,	O
the	O
genotoxicity	O
of	O
parthenolide	O
in	O
a	O
mouse	B-OG
model	O
was	O
determined	O
using	O
a	O
micronucleus	O
test	O
and	O
cyclophosphamide	O
as	O
the	O
positive	O
control	O
because	O
it	O
is	O
a	O
known	O
genotoxin	O
[	O
25	O
].	O

Micronuclei	O
are	O
masses	O
of	O
cytoplasmic	O
chromatin	O
that	O
appear	O
outside	O
the	O
main	O
nucleus	O
as	O
a	O
result	O
of	O
chromosomal	O
damage	O
or	O
damage	O
to	O
the	O
mitotic	O
apparatus	O
in	O
the	O
erythroblasts	O
of	O
the	O
test	O
species	O
,	O
and	O
they	O
can	O
be	O
used	O
as	O
an	O
indicator	O
of	O
the	O
effects	O
of	O
agents	O
that	O
cause	O
DNA	O
damage	O
[	O
26	O
].	O

In	O
mice	B-OG
,	O
micronuclei	O
in	O
mature	O
erythrocytes	O
in	O
peripheral	O
blood	O
live	O
approximately	O
1	O
month	O
,	O
providing	O
a	O
measure	O
of	O
average	O
chromosomal	O
damage	O
[	O
27	O
].	O

Our	O
results	O
showed	O
no	O
differences	O
in	O
the	O
frequency	O
of	O
MNPCE	O
compared	O
with	O
the	O
negative	O
control	O
,	O
demonstrating	O
no	O
toxic	O
effects	O
on	O
bone	O
marrow	O
at	O
the	O
dose	O
tested	O
(	O
3	O
.	O
75	O
mg	O
/	O
kg	O
body	O
weight	O
).	O

Electron	O
microscopic	O
studies	O
revealed	O
extensive	O
cytoplasmic	O
vacuolization	O
,	O
leading	O
to	O
the	O
examination	O
of	O
the	O
possibility	O
that	O
parthenolide	O
induces	O
autophagic	O
cell	O
death	O
.	O

Autophagy	O
cell	O
death	O
is	O
a	O
process	O
that	O
is	O
thought	O
to	O
occur	O
in	O
all	O
eukaryotes	B-OG
and	O
is	O
characterized	O
by	O
an	O
accumulation	O
of	O
autophagic	O
vacuoles	O
.	O

This	O
mechanism	O
occurs	O
for	O
energy	O
production	O
for	O
survival	O
when	O
cells	O
recycle	O
their	O
cytoplasmic	O
contents	O
during	O
periods	O
of	O
environmental	O
stress	O
or	O
certain	O
stages	O
of	O
development	O
.	O

A	O
double	O
-	O
membrane	O
vesicle	O
called	O
the	O
autophagosome	O
forms	O
in	O
the	O
cytosol	O
,	O
engulfing	O
organelles	O
and	O
bulk	O
cytoplasm	O
.	O

Subsequently	O
,	O
these	O
vesicles	O
fuse	O
with	O
lysosomes	O
,	O
where	O
their	O
contents	O
are	O
degraded	O
and	O
recycled	O
[	O
28	O
].	O

One	O
of	O
the	O
most	O
frequently	O
used	O
methods	O
to	O
examine	O
autophagy	O
is	O
staining	O
with	O
acidotropic	O
dyes	O
[	O
29	O
],	O
and	O
MDC	O
is	O
considered	O
an	O
autofluorescent	O
compound	O
and	O
specific	O
marker	O
for	O
autophagic	O
vacuoles	O
[	O
30	O
].	O

MDC	O
staining	O
is	O
only	O
obtained	O
when	O
the	O
compartments	O
into	O
which	O
it	O
loads	O
are	O
acidic	O
.	O

Neutralization	O
of	O
these	O
compartments	O
leads	O
to	O
a	O
swift	O
loss	O
of	O
MDC	O
staining	O
or	O
lack	O
of	O
MDC	O
uptake	O
[	O
31	O
].	O

Therefore	O
,	O
we	O
suggest	O
that	O
the	O
vacuoles	O
that	O
were	O
observed	O
under	O
a	O
transmission	O
electron	O
microscope	O
are	O
autophagosomes	O
.	O

Another	O
study	O
used	O
MDC	O
as	O
a	O
marker	O
to	O
analyze	O
the	O
molecular	O
level	O
of	O
the	O
machinery	O
involved	O
in	O
the	O
autophagic	O
process	O
[	O
32	O
]	O
and	O
was	O
also	O
used	O
to	O
demonstrate	O
that	O
antimicrobial	B-GP
peptides	I-GP
induce	O
autophagic	O
cell	O
death	O
in	O
L	B-OG
.	I-OG
donovani	I-OG
[	O
33	O
].	O

Amphotericin	O
B	O
was	O
used	O
as	O
a	O
positive	O
control	O
in	O
some	O
of	O
our	O
experiments	O
because	O
this	O
polyene	O
antibiotic	O
forms	O
aqueous	O
and	O
nonaqueous	O
pores	O
in	O
membranes	O
,	O
which	O
is	O
the	O
basis	O
of	O
leishmanicidal	O
action	O
[	O
34	O
].	O

Using	O
transmission	O
electron	O
microscopy	O
,	O
we	O
could	O
see	O
the	O
loss	O
of	O
membrane	O
integrity	O
induced	O
by	O
this	O
antimicrobial	O
agent	O
.	O

Similarly	O
,	O
alterations	O
in	O
the	O
cytoplasmic	O
membrane	O
,	O
including	O
membrane	O
blebbing	O
and	O
disruption	O
,	O
could	O
be	O
visualized	O
in	O
axenic	O
amastigotes	O
treated	O
with	O
parthenolide	O
.	O

Studies	O
have	O
shown	O
that	O
a	O
flow	O
cytometric	O
membrane	O
potential	O
assay	O
can	O
be	O
used	O
as	O
a	O
reliable	O
tool	O
for	O
studying	O
the	O
interactions	O
between	O
amphotericin	O
B	O
and	O
the	O
Leishmania	B-OG
membrane	O
[	O
35	O
].	O

Alterations	O
in	O
membrane	O
permeability	O
are	O
detected	O
by	O
propidium	O
iodide	O
nucleic	O
acid	O
stain	O
that	O
selectively	O
passes	O
through	O
plasma	O
membranes	O
and	O
bind	O
to	O
DNA	O
,	O
emitting	O
high	O
fluorescence	O
when	O
excited	O
by	O
an	O
argon	O
ion	O
laser	O
[	O
36	O
].	O

Since	O
its	O
introduction	O
,	O
the	O
propidium	O
iodide	O
flow	O
cytometric	O
assay	O
has	O
also	O
been	O
widely	O
used	O
as	O
a	O
quantitative	O
measure	O
of	O
cell	O
apoptosis	O
.	O

During	O
apoptosis	O
,	O
DNA	O
fragmentation	O
occurs	O
,	O
with	O
a	O
subsequent	O
loss	O
of	O
cellular	O
DNA	O
content	O
[	O
37	O
].	O

Terpenoic	O
compounds	O
can	O
produce	O
major	O
changes	O
in	O
the	O
cellular	O
and	O
mitochondrial	O
membrane	O
structures	O
of	O
different	O
pathogenic	O
agents	O
,	O
modifying	O
their	O
permeability	O
and	O
integrity	O
[	O
20	O
].	O

Ultrastructural	O
findings	O
also	O
revealed	O
mitochondrial	O
damage	O
induced	O
by	O
parthenolide	O
.	O

We	O
used	O
flow	O
cytometry	O
analysis	O
to	O
determine	O
whether	O
the	O
compound	O
interferes	O
with	O
the	O
mitochondrial	O
membrane	O
potential	O
of	O
the	O
amastigotes	O
.	O

The	O
flow	O
cytometry	O
results	O
showed	O
that	O
transmembrane	O
potential	O
decreased	O
,	O
reflected	O
by	O
a	O
reduction	O
of	O
rhodamine	O
123	O
fluorescence	O
.	O

Rhodamine	O
123	O
is	O
a	O
fluorescent	O
cationic	O
stain	O
for	O
mitochondria	O
in	O
living	O
cells	O
and	O
is	O
subsequently	O
washed	O
out	O
of	O
the	O
cells	O
once	O
the	O
mitochondrion	O
’	O
s	O
membrane	O
potential	O
is	O
lost	O
[	O
38	O
].	O

The	O
present	O
results	O
indicated	O
an	O
increase	O
in	O
proton	O
permeability	O
through	O
the	O
internal	O
mitochondrial	O
membrane	O
,	O
inhibition	O
of	O
electron	O
transport	O
,	O
or	O
decrease	O
in	O
mitochondrial	O
substrate	O
transport	O
/	O
oxidation	O
,	O
which	O
would	O
impair	O
proton	O
pumping	O
by	O
mitochondrial	O
complexes	O
and	O
reduce	O
adenosine	O
triphosphate	O
synthesis	O
,	O
resulting	O
in	O
parasite	O
cell	O
death	O
[	O
39	O
].	O

CCCP	O
was	O
used	O
as	O
positive	O
control	O
because	O
it	O
is	O
an	O
uncoupler	O
of	O
oxidative	O
phosphorylation	O
and	O
reduces	O
mitochondrial	O
membrane	O
potential	O
by	O
directly	O
attacking	O
the	O
proton	O
gradient	O
across	O
the	O
inner	O
mitochondrial	O
membrane	O
[	O
12	O
,	O
40	O
].	O

Amastigotes	O
treated	O
with	O
parthenolide	O
presented	O
severe	O
plasma	O
membrane	O
and	O
mitochondrial	O
damage	O
,	O
suggesting	O
an	O
autophagic	O
process	O
[	O
39	O
].	O

Treatment	O
with	O
parthenolide	O
induced	O
shedding	O
of	O
the	O
membranes	O
into	O
the	O
flagellar	O
pocket	O
,	O
appearing	O
as	O
concentric	O
membranes	O
and	O
suggesting	O
intense	O
exocytic	O
activity	O
because	O
this	O
site	O
is	O
where	O
endocytosis	O
and	O
exocytosis	O
occur	O
in	O
trypanosomatids	O
.	O

Treatment	O
of	O
promastigote	O
forms	O
of	O
L	B-OG
.	I-OG
amazonensis	I-OG
with	O
edelfosine	O
for	O
1	O
day	O
[	O
41	O
]	O
and	O
parthenolide	O
for	O
3	O
days	O
[	O
10	O
]	O
also	O
led	O
to	O
the	O
appearance	O
of	O
a	O
large	O
number	O
of	O
vesicles	O
inside	O
the	O
flagellar	O
pocket	O
,	O
suggesting	O
a	O
process	O
of	O
exacerbated	O
protein	O
production	O
by	O
cells	O
as	O
they	O
attempt	O
to	O
survive	O
.	O

Other	O
studies	O
indicated	O
that	O
the	O
plasma	O
membrane	O
of	O
human	B-OG
promyelocytic	O
leukemic	O
HL	O
-	O
60	O
cells	O
appears	O
to	O
be	O
one	O
of	O
the	O
targets	O
of	O
parthenolide	O
because	O
its	O
integrity	O
is	O
lost	O
very	O
early	O
during	O
cell	O
death	O
,	O
reflected	O
by	O
atypical	O
apoptosis	O
and	O
primary	O
necrosis	O
(	O
i	O
.	O
e	O
.,	O
lysis	O
of	O
the	O
membrane	O
)	O
[	O
42	O
].	O

The	O
lipid	O
spin	O
probe	O
5	O
-	O
DSA	O
was	O
incorporated	O
into	O
the	O
plasmatic	O
membrane	O
of	O
Leishmania	B-OG
in	O
the	O
usual	O
way	O
,	O
and	O
the	O
EPR	O
spectra	O
obtained	O
were	O
typical	O
for	O
cell	O
membranes	O
.	O

Interestingly	O
,	O
the	O
spectra	O
of	O
the	O
Leishmania	B-OG
membrane	O
were	O
very	O
similar	O
to	O
those	O
for	O
the	O
same	O
spin	O
label	O
in	O
erythrocyte	O
membranes	O
[	O
43	O
].	O

The	O
erythrocyte	O
membrane	O
of	O
spin	O
-	O
labeled	O
lipids	O
has	O
been	O
well	O
characterized	O
by	O
EPR	O
spectroscopy	O
and	O
is	O
considered	O
to	O
have	O
certain	O
rigidity	O
,	O
particularly	O
because	O
of	O
its	O
high	O
content	O
of	O
protein	O
and	O
cholesterol	O
.	O

The	O
presence	O
of	O
sesquiterpene	O
parthenolide	O
significantly	O
increased	O
the	O
rigidity	O
of	O
the	O
membrane	O
of	O
Leishmania	B-OG
when	O
applied	O
to	O
the	O
cell	O
suspension	O
at	O
a	O
ratio	O
of	O
3	O
×	O
109	O
parthenolide	O
molecules	O
/	O
cell	O
.	O

Parthenolide	O
also	O
showed	O
dose	O
-	O
dependent	O
anti	O
-	O
Leishmania	B-OG
activity	O
against	O
the	O
amastigote	O
form	O
.	O

The	O
IC50	O
was	O
1	O
.	O
3	O
μM	O
parthenolide	O
/	O
ml	O
for	O
a	O
cell	O
concentration	O
of	O
1	O
×	O
106	O
cell	O
/	O
ml	O
.	O

Therefore	O
,	O
the	O
effect	O
of	O
parthenolide	O
against	O
the	O
amastigote	O
forms	O
of	O
Leishmania	B-OG
was	O
observed	O
at	O
a	O
ratio	O
of	O
7	O
.	O
8	O
×	O
108	O
parthenolide	O
molecules	O
/	O
cell	O
.	O

The	O
greatest	O
change	O
in	O
membrane	O
fluidity	O
was	O
observed	O
at	O
a	O
concentration	O
3	O
.	O
8	O
-	O
fold	O
higher	O
than	O
for	O
growth	O
inhibition	O
.	O

Membrane	O
stiffness	O
,	O
assessed	O
by	O
EPR	O
spectroscopy	O
of	O
the	O
spin	O
label	O
,	O
has	O
been	O
associated	O
with	O
lipid	O
peroxidation	O
[	O
44	O
,	O
45	O
].	O

A	O
detailed	O
study	O
of	O
the	O
interaction	O
between	O
parthenolide	O
and	O
membranes	O
and	O
their	O
role	O
as	O
a	O
pro	O
-	O
oxidant	O
in	O
simpler	O
systems	O
is	O
necessary	O
to	O
determine	O
whether	O
the	O
membrane	O
rigidity	O
observed	O
here	O
was	O
attributable	O
to	O
lipid	O
peroxidation	O
.	O

Conclusions	O

Our	O
results	O
indicated	O
that	O
the	O
antileishmanial	O
action	O
of	O
parthenolide	O
is	O
associated	O
with	O
autophagic	O
vacuole	O
appearance	O
,	O
membrane	O
stiffness	O
,	O
the	O
loss	O
of	O
membrane	O
integrity	O
,	O
and	O
mitochondrial	O
dysfunction	O
.	O

These	O
results	O
indicate	O
that	O
parthenolide	O
induced	O
amastigote	O
cell	O
death	O
by	O
autophagy	O
,	O
but	O
other	O
mechanisms	O
of	O
cell	O
death	O
cannot	O
be	O
dismissed	O
,	O
such	O
as	O
apoptosis	O
and	O
necrosis	O
.	O

Considering	O
the	O
limited	O
repertoire	O
of	O
existing	O
antileishmanial	O
compounds	O
,	O
continuously	O
developing	O
new	O
leishmanicidal	O
compounds	O
is	O
essential	O
.	O

In	O
the	O
ongoing	O
search	O
for	O
the	O
best	O
antileishmanial	O
compounds	O
,	O
products	O
derived	O
from	O
plants	B-OG
are	O
gaining	O
ground	O
.	O

The	O
isolation	O
and	O
purification	O
of	O
the	O
active	O
components	O
of	O
medicinal	O
plants	B-OG
has	O
been	O
one	O
the	O
greatest	O
advances	O
.	O

Additionally	O
,	O
delineation	O
of	O
the	O
biochemical	O
mechanisms	O
involved	O
in	O
mediating	O
effect	O
of	O
these	O
compounds	O
would	O
help	O
develop	O
new	O
chemotherapeutic	O
approaches	O
.	O

Methods	O

Drugs	O

Parthenolide	O
(	O
minimum	O
90	O
%)	O
was	O
purchased	O
from	O
Sigma	O
-	O
Aldrich	O
(	O
Steinheim	O
,	O
Germany	O
).	O

Amphotericin	O
B	O
(	O
Cristália	O
,	O
Produtos	O
Químicos	O
Farmacêuticos	O
Ltda	O
,	O
Itapira	O
,	O
SP	O
,	O
Brazil	O
)	O
was	O
used	O
as	O
a	O
positive	O
control	O
.	O

In	O
all	O
of	O
the	O
tests	O
,	O
0	O
.	O
05	O
%	O
dimethyl	O
sulfoxide	O
(	O
DMSO	O
;	O
Sigma	O
,	O
St	O
.	O
Louis	O
,	O
MO	O
,	O
USA	O
)	O
was	O
used	O
to	O
dissolve	O
the	O
highest	O
dose	O
of	O
the	O
compounds	O
and	O
had	O
no	O
effect	O
on	O
the	O
parasites	O
’	O
proliferation	O
or	O
morphology	O
.	O

Axenic	O
amastigotes	O

Promastigotes	O
of	O
the	O
Leishmania	B-OG
species	O
differentiate	O
to	O
amastigotes	O
with	O
the	O
combination	O
of	O
low	O
pH	O
and	O
high	O
temperature	O
[	O
46	O
].	O

The	O
WHOM	O
/	O
BR	O
/	O
75	O
/	O
Josefa	O
strain	O
of	O
Leishmania	B-OG
amazonensis	I-OG
,	O
isolated	O
by	O
C	O
.	O
A	O
.	O

Cuba	O
-	O
Cuba	O
(	O
University	O
of	O
Brasília	O
,	O
Brasília	O
,	O
Distrito	O
Federal	O
,	O
Brazil	O
)	O
from	O
a	O
human	B-OG
case	O
of	O
diffuse	B-DS
cutaneous	I-DS
leishmaniasis	I-DS
,	O
was	O
used	O
in	O
the	O
present	O
study	O
.	O

Axenic	O
amastigote	O
cultures	O
were	O
obtained	O
by	O
the	O
in	O
vitro	O
differentiation	O
of	O
promastigotes	O
from	O
the	O
stationary	O
phase	O
in	O
25	O
cm2	O
tissue	O
culture	O
flasks	O
by	O
progressive	O
temperature	O
increase	O
and	O
pH	O
decrease	O
[	O
47	O
].	O

The	O
cultures	O
were	O
maintained	O
at	O
32	O
°	O
C	O
in	O
Schneider	O
’	O
s	O
insect	O
medium	O
(	O
Sigma	O
,	O
St	O
.	O
Louis	O
,	O
MO	O
,	O
USA	O
),	O
pH	O
4	O
.	O
6	O
,	O
with	O
20	O
%	O
fetal	O
bovine	O
serum	O
through	O
weekly	O
serial	O
sub	O
-	O
culturing	O
for	O
further	O
studies	O
.	O

Antiproliferative	O
effect	O

For	O
the	O
parasite	O
growth	O
inhibition	O
assays	O
,	O
L	B-OG
.	I-OG
amazonensis	I-OG
axenic	O
amastigotes	O
were	O
harvested	O
during	O
the	O
exponential	O
phase	O
of	O
growth	O
,	O
and	O
106	O
cells	O
were	O
added	O
to	O
each	O
well	O
of	O
a	O
24	O
-	O
well	O
plate	O
and	O
treated	O
with	O
different	O
concentrations	O
of	O
parthenolide	O
and	O
amphotericin	O
B	O
.	O

Medium	O
alone	O
and	O
0	O
.	O
05	O
%	O
DMSO	O
were	O
used	O
as	O
negative	O
controls	O
.	O

For	O
each	O
treatment	O
,	O
the	O
parasites	O
were	O
observed	O
and	O
counted	O
daily	O
using	O
a	O
Neubauer	O
chamber	O
with	O
an	O
optical	O
microscope	O
.	O

Each	O
experiment	O
was	O
performed	O
in	O
duplicate	O
and	O
twice	O
on	O
different	O
occasions	O
.	O

The	O
antiproliferative	O
effect	O
(	O
percentage	O
of	O
growth	O
inhibition	O
)	O
was	O
evaluated	O
with	O
5	O
day	O
treatment	O
,	O
and	O
the	O
data	O
are	O
expressed	O
as	O
the	O
mean	O
±	O
standard	O
error	O
of	O
the	O
mean	O
(	O
Microsoft	O
Excel	O
).	O

The	O
corresponding	O
50	O
%	O
and	O
90	O
%	O
inhibitory	O
concentrations	O
(	O
IC50	O
and	O
IC90	O
)	O
were	O
determined	O
from	O
the	O
concentration	O
-	O
response	O
curves	O
(	O
Excel	O
software	O
).	O

Data	O
were	O
compared	O
via	O
one	O
-	O
way	O
analysis	O
of	O
variance	O
(	O
ANOVA	O
)	O
followed	O
by	O
Tukey	O
’	O
s	O
multiple	O
range	O
test	O
for	O
statistically	O
significant	O
differences	O
at	O
p	O
<	O
0	O
.	O
05	O
.	O

Activity	O
of	O
parthenolide	O
in	O
infection	B-DS
of	O
murine	O
macrophages	O

The	O
effect	O
of	O
parthenolide	O
on	O
L	B-OG
.	I-OG
amazonensis	I-OG
-	O
infected	O
mouse	B-OG
peritoneal	O
macrophages	O
was	O
evaluated	O
.	O

The	O
experimental	O
protocol	O
was	O
approved	O
by	O
the	O
Animal	O
Ethics	O
Committee	O
of	O
the	O
Universidade	O
Estadual	O
de	O
Maringá	O
(	O
no	O
.	O
013	O
/	O
2010	O
).	O

BALB	B-OG
/	I-OG
c	I-OG
mice	I-OG
resident	O
peritoneal	O
cells	O
were	O
harvested	O
in	O
phosphate	O
-	O
buffered	O
saline	O
(	O
PBS	O
;	O
0	O
.	O
01	O
M	O
,	O
pH	O
7	O
.	O
2	O
)	O
and	O
centrifuged	O
,	O
and	O
the	O
sediment	O
was	O
resuspended	O
in	O
RPMI	O
1640	O
medium	O
supplemented	O
with	O
10	O
%	O
fetal	O
bovine	O
serum	O
.	O

Cells	O
(	O
1	O
×	O
105	O
)	O
were	O
seeded	O
on	O
13	O
-	O
mm	O
coverslips	O
in	O
24	O
-	O
well	O
plates	O
and	O
incubated	O
at	O
37	O
°	O
C	O
in	O
a	O
5	O
%	O
CO2	O
atmosphere	O
.	O

After	O
15	O
h	O
,	O
macrophages	O
were	O
infected	O
with	O
promastigotes	O
at	O
a	O
10	O
:	O
1	O
parasite	O
:	O
cell	O
ratio	O
and	O
incubated	O
again	O
for	O
6	O
h	O
.	O

The	O
remaining	O
noninternalized	O
parasites	O
were	O
removed	O
.	O

The	O
infected	O
host	O
cells	O
were	O
treated	O
with	O
parthenolide	O
at	O
concentrations	O
of	O
4	O
.	O
0	O
,	O
3	O
.	O
2	O
,	O
2	O
.	O
4	O
,	O
and	O
1	O
.	O
6	O
μM	O
.	O

After	O
24	O
h	O
,	O
the	O
coverslips	O
were	O
washed	O
with	O
PBS	O
,	O
fixed	O
in	O
methanol	O
,	O
stained	O
with	O
Giemsa	O
,	O
mounted	O
in	O
Entellan	O
(	O
Merck	O
),	O
and	O
examined	O
under	O
an	O
optical	O
microscope	O
.	O

The	O
rate	O
of	O
cell	O
infection	B-DS
and	O
number	O
of	O
amastigotes	O
per	O
cell	O
were	O
evaluated	O
by	O
counting	O
200	O
random	O
cells	O
in	O
duplicate	O
cultures	O
in	O
at	O
least	O
two	O
independent	O
experiments	O
.	O

The	O
survival	O
index	O
was	O
calculated	O
by	O
multiplying	O
the	O
percentage	O
of	O
infected	O
macrophages	O
and	O
mean	O
number	O
of	O
internalized	O
parasites	O
per	O
macrophage	O
.	O

Data	O
were	O
compared	O
via	O
one	O
-	O
way	O
analysis	O
of	O
variance	O
(	O
ANOVA	O
)	O
followed	O
by	O
Tukey	O
’	O
s	O
multiple	O
range	O
test	O
for	O
statistically	O
significant	O
differences	O
at	O
p	O
<	O
0	O
.	O
05	O
.	O

Genotoxicity	O
study	O

To	O
assess	O
the	O
toxicity	O
of	O
parthenolide	O
in	O
mice	B-OG
,	O
a	O
micronucleus	O
test	O
was	O
conducted	O
in	O
groups	O
of	O
five	O
male	O
and	O
five	O
female	O
Swiss	B-OG
albino	I-OG
mice	I-OG
(	O
Mus	B-OG
musculus	I-OG
)	O
that	O
weighed	O
approximately	O
42	O
g	O
.	O

The	O
animals	B-OG
were	O
obtained	O
from	O
the	O
Central	O
Animal	O
House	O
of	O
the	O
Universidade	O
Estadual	O
de	O
Maringá	O
,	O
Paraná	O
,	O
Brazil	O
.	O

They	O
were	O
housed	O
in	O
plastic	O
cages	O
at	O
22	O
±	O
1	O
°	O
C	O
and	O
55	O
±	O
10	O
%	O
humidity	O
,	O
with	O
a	O
12	O
h	O
/	O
12	O
h	O
light	O
/	O
dark	O
cycle	O
and	O
free	O
access	O
to	O
water	O
and	O
food	O
(	O
Nuvilab	O
Cr1	O
).	O

The	O
study	O
was	O
conducted	O
according	O
to	O
experimental	O
standards	O
approved	O
by	O
the	O
Animal	O
Ethics	O
Committee	O
of	O
the	O
Universidade	O
Estadual	O
de	O
Maringá	O
(	O
protocol	O
no	O
.	O
013	O
/	O
2010	O
).	O

The	O
animals	B-OG
received	O
3	O
.	O
75	O
mg	O
parthenolide	O
/	O
kg	O
body	O
weight	O
suspended	O
in	O
10	O
%	O
DMSO	O
by	O
oral	O
gavage	O
.	O

The	O
negative	O
control	O
was	O
a	O
vehicle	O
group	O
,	O
and	O
the	O
positive	O
control	O
was	O
a	O
group	O
that	O
received	O
40	O
mg	O
cyclophosphamide	O
/	O
kg	O
body	O
weight	O
.	O

The	O
mice	B-OG
were	O
examined	O
regularly	O
for	O
mortality	O
and	O
clinical	O
signs	O
of	O
toxicity	O
until	O
sacrifice	O
by	O
carbon	O
dioxide	O
asphyxiation	O
,	O
which	O
occurred	O
24	O
h	O
after	O
treatment	O
.	O

Both	O
femurs	O
were	O
dissected	O
,	O
and	O
bone	O
marrow	O
was	O
flushed	O
with	O
fetal	O
calf	O
serum	O
.	O

After	O
centrifugation	O
for	O
5	O
min	O
at	O
2	O
,	O
000	O
×	O
g	O
,	O
10	O
μl	O
of	O
the	O
sediment	O
was	O
smeared	O
on	O
glass	O
slides	O
and	O
air	O
-	O
dried	O
.	O

The	O
smears	O
were	O
fixed	O
with	O
absolute	O
methanol	O
for	O
5	O
min	O
and	O
stained	O
with	O
May	O
-	O
Grunwald	O
-	O
Giemsa	O
to	O
detect	O
micronucleated	O
polychromatic	O
erythrocytes	O
(	O
MNPCE	O
).	O

The	O
number	O
of	O
micronucleated	O
cells	O
was	O
counted	O
in	O
2	O
,	O
000	O
reticulocytes	O
per	O
animal	B-OG
using	O
an	O
Olympus	O
BH	O
-	O
2	O
microscope	O
at	O
1	O
,	O
000	O
×	O
magnification	O
[	O
26	O
].	O

The	O
statistical	O
analyses	O
were	O
made	O
with	O
a	O
one	O
-	O
way	O
analysis	O
of	O
variance	O
(	O
ANOVA	O
)	O
followed	O
by	O
Dunnet	O
test	O
.	O

Differences	O
were	O
considered	O
significant	O
at	O
p	O
value	O
of	O
less	O
than	O
0	O
.	O
05	O
.	O

Scanning	O
and	O
transmission	O
electron	O
microscopy	O

After	O
treatment	O
with	O
the	O
IC50	O
(	O
72	O
h	O
)	O
of	O
parthenolide	O
,	O
axenic	O
amastigotes	O
were	O
washed	O
in	O
PBS	O
and	O
fixed	O
in	O
2	O
.	O
5	O
%	O
glutaraldehyde	O
in	O
0	O
.	O
1	O
M	O
sodium	O
cacodylate	O
buffer	O
at	O
4ºC	O
.	O

For	O
scanning	O
electron	O
microscopy	O
,	O
amastigotes	O
were	O
placed	O
on	O
a	O
specimen	O
support	O
with	O
a	O
poly	O
-	O
L	O
-	O
lysine	O
-	O
coated	O
coverslip	O
and	O
washed	O
in	O
cacodylate	O
buffer	O
.	O

The	O
cells	O
were	O
dehydrated	O
in	O
an	O
increasing	O
ethanol	O
gradient	O
,	O
critical	O
-	O
point	O
-	O
dried	O
in	O
CO2	O
,	O
sputter	O
-	O
coated	O
with	O
gold	O
,	O
and	O
observed	O
in	O
a	O
Shimadzu	O
SS	O
-	O
550	O
SEM	O
scanning	O
electron	O
microscope	O
.	O

For	O
transmission	O
electron	O
microscopy	O
,	O
amastigote	O
forms	O
were	O
treated	O
with	O
the	O
IC50	O
of	O
parthenolide	O
and	O
the	O
IC50	O
of	O
amphotericin	O
B	O
and	O
fixed	O
as	O
described	O
above	O
.	O

The	O
cells	O
were	O
postfixed	O
in	O
a	O
solution	O
that	O
contained	O
1	O
%	O
osmium	O
tetroxide	O
,	O
0	O
.	O
8	O
%	O
potassium	O
ferrocyanide	O
,	O
and	O
10	O
mM	O
calcium	O
chloride	O
in	O
0	O
.	O
1	O
M	O
cacodylate	O
buffer	O
,	O
dehydrated	O
in	O
an	O
increasing	O
acetone	O
gradient	O
,	O
and	O
embedded	O
in	O
Epon	O
resin	O
.	O

Ultrathin	O
sections	O
were	O
stained	O
with	O
uranyl	O
acetate	O
and	O
lead	O
citrate	O
,	O
and	O
the	O
images	O
were	O
examined	O
in	O
a	O
Zeiss	O
900	O
transmission	O
electron	O
microscope	O
.	O

Fluorescence	O
of	O
monodansylcadaverine	O
during	O
cell	O
death	O

Axenic	O
amastigotes	O
were	O
treated	O
with	O
IC50	O
and	O
IC90	O
equivalents	O
of	O
parthenolide	O
.	O

After	O
72	O
h	O
,	O
the	O
cells	O
were	O
washed	O
and	O
resuspended	O
in	O
PBS	O
.	O

To	O
verify	O
the	O
induction	O
of	O
autophagy	O
by	O
parthenolide	O
,	O
the	O
cells	O
were	O
incubated	O
with	O
0	O
.	O
05	O
mM	O
monodansylcadaverine	O
(	O
MDC	O
)	O
at	O
37	O
°	O
C	O
for	O
10	O
min	O
.	O

After	O
incubation	O
,	O
the	O
cells	O
were	O
washed	O
three	O
times	O
with	O
PBS	O
to	O
remove	O
excess	O
MDC	O
,	O
immediately	O
analyzed	O
by	O
fluorescence	O
microscopy	O
at	O
an	O
excitation	O
wavelength	O
of	O
360	O
–	O
380	O
nm	O
and	O
emission	O
wavelength	O
of	O
525	O
nm	O
,	O
and	O
photographed	O
using	O
a	O
charge	O
-	O
coupled	O
-	O
device	O
camera	O
.	O

This	O
study	O
was	O
qualitative	O
.	O

Flow	O
cytometry	O

The	O
antileishmanial	O
activity	O
of	O
parthenolide	O
(	O
20	O
and	O
40	O
μM	O
)	O
on	O
the	O
integrity	O
of	O
the	O
plasma	O
membrane	O
and	O
mitochondrial	O
membrane	O
potential	O
of	O
axenic	O
amastigotes	O
(	O
5	O
×	O
106	O
cells	O
/	O
ml	O
)	O
was	O
determined	O
after	O
3	O
h	O
treatment	O
.	O

Amphotericin	O
B	O
(	O
5	O
.	O
0	O
μM	O
)	O
and	O
carbonyl	O
cyanide	O
m	O
-	O
chlorophenylhydrazone	O
(	O
200	O
μM	O
)	O
were	O
used	O
as	O
positive	O
controls	O
.	O

Untreated	O
amastigotes	O
were	O
used	O
as	O
a	O
negative	O
control	O
.	O

Each	O
flow	O
-	O
cytometric	O
technique	O
was	O
evaluated	O
by	O
repeating	O
each	O
experiment	O
three	O
times	O
to	O
verify	O
reproducibility	O
.	O

The	O
integrity	O
of	O
the	O
plasma	O
membrane	O
was	O
assessed	O
using	O
L	B-OG
.	I-OG
amazonensis	I-OG
amastigotes	O
at	O
an	O
average	O
density	O
of	O
5	O
×	O
106	O
cells	O
suspended	O
in	O
500	O
μl	O
PBS	O
and	O
stained	O
with	O
50	O
μl	O
propidium	O
iodide	O
(	O
2	O
μg	O
/	O
ml	O
)	O
for	O
5	O
min	O
at	O
room	O
temperature	O
.	O

To	O
measure	O
mitochondrial	O
membrane	O
potential	O
(	O
ΔΨm	O
),	O
1	O
ml	O
of	O
saline	O
that	O
contained	O
1	O
×	O
106	O
of	O
treated	O
amastigotes	O
was	O
mixed	O
with	O
1	O
μl	O
rhodamine	O
123	O
(	O
5	O
mg	O
/	O
mL	O
)	O
for	O
15	O
min	O
at	O
37	O
°	O
C	O
.	O

The	O
cells	O
were	O
washed	O
,	O
resuspended	O
in	O
PBS	O
,	O
and	O
incubated	O
at	O
the	O
same	O
temperature	O
for	O
30	O
min	O
.	O

A	O
total	O
of	O
10	O
,	O
000	O
events	O
were	O
analyzed	O
per	O
sample	O
using	O
a	O
FACSCalibur	O
cytometer	O
,	O
and	O
numeric	O
data	O
were	O
processed	O
with	O
Cellquest	O
software	O
(	O
both	O
from	O
Becton	O
Dickinson	O
).	O

Propidium	O
iodide	O
and	O
rhodamine	O
123	O
are	O
excited	O
with	O
a	O
480	O
nm	O
argon	O
ion	O
laser	O
,	O
and	O
fluorescence	O
emission	O
occurs	O
at	O
560	O
–	O
580	O
nm	O
and	O
515	O
–	O
530	O
nm	O
,	O
respectively	O
.	O

Electron	O
paramagnetic	O
resonance	O
spectroscopy	O

Spin	O
-	O
label	O
5	O
-	O
doxyl	O
stearic	O
acid	O
(	O
5	O
-	O
DSA	O
),	O
with	O
a	O
nitroxide	O
radical	O
moiety	O
(	O
doxyl	O
)	O
in	O
the	O
fifth	O
carbon	O
atom	O
of	O
the	O
acyl	O
chain	O
,	O
was	O
purchased	O
from	O
Sigma	O
(	O
St	O
.	O
Louis	O
,	O
MO	O
,	O
USA	O
).	O

A	O
small	O
aliquot	O
(	O
3	O
μl	O
)	O
of	O
stock	O
solution	O
of	O
the	O
spin	O
label	O
in	O
ethanol	O
(	O
2	O
mg	O
/	O
ml	O
)	O
was	O
transferred	O
to	O
a	O
glass	O
tube	O
.	O

After	O
the	O
solvent	O
evaporated	O
,	O
approximately	O
2	O
.	O
4	O
×	O
108	O
cells	O
of	O
Leishmania	B-OG
suspended	O
in	O
40	O
μl	O
PBS	O
was	O
added	O
to	O
the	O
film	O
of	O
the	O
spin	O
label	O
with	O
gentle	O
agitation	O
.	O

In	O
a	O
second	O
tube	O
,	O
6	O
μl	O
of	O
a	O
stock	O
solution	O
of	O
parthenolide	O
in	O
chloroform	O
(	O
201	O
mM	O
)	O
was	O
added	O
.	O

After	O
evaporation	O
of	O
the	O
solvent	O
,	O
the	O
first	O
spin	O
-	O
labeled	O
cell	O
suspension	O
was	O
placed	O
on	O
the	O
parthenolide	O
film	O
and	O
gently	O
agitated	O
.	O

The	O
cells	O
were	O
then	O
introduced	O
into	O
a	O
1	O
mm	O
inner	O
diameter	O
capillary	O
column	O
for	O
electron	O
paramagnetic	O
resonance	O
(	O
EPR	O
)	O
measurements	O
,	O
which	O
was	O
sealed	O
by	O
flame	O
.	O

Samples	O
were	O
also	O
prepared	O
that	O
contained	O
double	O
and	O
triple	O
the	O
concentrations	O
of	O
parthenolide	O
used	O
in	O
the	O
first	O
sample	O
(	O
using	O
12	O
and	O
18	O
μl	O
of	O
the	O
solution	O
of	O
parthenolide	O
in	O
chloroform	O
,	O
respectively	O
).	O

Electron	O
paramagnetic	O
resonance	O
spectroscopy	O
was	O
performed	O
with	O
a	O
Bruker	O
ESP	O
300	O
spectrometer	O
(	O
Rheinstetten	O
,	O
Germany	O
)	O
equipped	O
with	O
an	O
ER	O
4102	O
ST	O
resonator	O
.	O

The	O
instrument	O
settings	O
were	O
the	O
following	O
:	O
microwave	O
power	O
,	O
10	O
mW	O
;	O
modulation	O
frequency	O
,	O
100	O
KHz	O
;	O
modulation	O
amplitude	O
,	O
1	O
.	O
0	O
G	O
.	O

Electron	O
paramagnetic	O
resonance	O
spectra	O
simulations	O
were	O
performed	O
using	O
the	O
NLLS	O
program	O
developed	O
by	O
Budil	O
and	O
coworkers	O
[	O
48	O
].	O

In	O
the	O
spectral	O
calculations	O
,	O
the	O
NLLS	O
program	O
includes	O
the	O
magnetic	O
g	O
-	O
and	O
A	O
-	O
tensors	O
and	O
rotational	O
diffusion	O
tensor	O
,	O
R	O
,	O
which	O
are	O
expressed	O
in	O
a	O
system	O
of	O
Cartesian	O
axes	O
fixed	O
in	O
the	O
spin	O
-	O
labeled	O
molecule	O
.	O

To	O
reduce	O
the	O
number	O
of	O
parameters	O
in	O
the	O
fittings	O
and	O
simplify	O
the	O
simulation	O
,	O
the	O
average	O
rotational	O
diffusion	O
rate	O
,	O
R	O
bar	O
,	O
was	O
calculated	O
by	O
the	O
fitting	O
program	O
using	O
the	O
relationship	O
R	O
bar	O
=	O
(	O
R	O
per	O
2	O
•	O
R	O
par	O
)	O
1	O
/	O
3	O
,	O
in	O
which	O
R	O
per	O
is	O
the	O
perpendicular	O
component	O
of	O
the	O
rotational	O
diffusion	O
,	O
and	O
R	O
par	O
is	O
the	O
parallel	O
component	O
of	O
the	O
rotational	O
diffusion	O
.	O
R	O
bar	O
was	O
converted	O
to	O
the	O
parameter	O
rotational	O
correlation	O
time	O
,	O
τ	O
c	O
,	O
following	O
the	O
relationship	O
τ	O
c	O
=	O
1	O
/	O
6	O
R	O
bar	O
.	O

Similar	O
to	O
previous	O
studies	O
[	O
49	O
,	O
50	O
],	O
the	O
magnetic	O
parameters	O
were	O
determined	O
based	O
on	O
a	O
global	O
analysis	O
of	O
the	O
overall	O
spectra	O
obtained	O
in	O
this	O
work	O
,	O
and	O
all	O
of	O
the	O
EPR	O
spectra	O
were	O
simulated	O
using	O
the	O
same	O
predetermined	O
parameters	O
.	O

In	O
this	O
work	O
,	O
the	O
spectra	O
were	O
simulated	O
with	O
a	O
model	O
of	O
two	O
spectral	O
components	O
.	O

Competing	O
interests	O

The	O
authors	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O

Authors	O
’	O
contributions	O

TST	O
conceived	O
and	O
designed	O
the	O
study	O
,	O
carried	O
out	O
all	O
the	O
experimental	O
studies	O
and	O
drafted	O
the	O
manuscript	O
.	O

TUN	O
participated	O
in	O
the	O
design	O
of	O
the	O
study	O
.	O

AA	O
assisted	O
with	O
EPR	O
spectra	O
and	O
helped	O
to	O
draft	O
the	O
manuscript	O
.	O

CVN	O
conceived	O
of	O
the	O
study	O
,	O
and	O
participated	O
in	O
its	O
design	O
and	O
coordination	O
and	O
helped	O
to	O
draft	O
the	O
manuscript	O
.	O

All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

